Lakewood-Amedex Biotherapeutics, Inc.
LABT
$2.18
-$0.14-6.03%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -308.53% | -23.95% | 60.94% | -190.78% | -21.55% |
| Total Depreciation and Amortization | 0.66% | 0.66% | 0.66% | 0.67% | 0.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5,301.08% | -1.07% | -96.12% | 2,362.37% | -9.11% |
| Change in Net Operating Assets | -272.67% | 102.07% | 290.94% | -8.31% | 31.67% |
| Cash from Operations | -501.66% | 17.13% | 30.82% | -19.94% | -25.86% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -41.44% | -- | -- | -100.00% | 550.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5,241.68% | -- | -- | -100.00% | 550.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,245.13% | 46.75% | 30.82% | -177.08% | 487.75% |